Group 1 - Chuanfa Longmang's wholly-owned subsidiary plans to invest 660 million yuan to establish a joint venture for a 175,000 tons/year high-pressure lithium iron phosphate project in Sichuan Mianzhu, with a total investment of 1.961 billion yuan [1] - The joint venture will be co-owned by Jiangxi Shenghua New Materials (51%) and Deyang Chuanfa Longmang (49%) [1] - Chuanfa Longmang specializes in the production and sales of various phosphate products, including lithium iron phosphate [1] Group 2 - Sino Medical's COMETIU self-expanding intracranial drug-coated stent system registration application was not approved by the National Medical Products Administration [2] - Sino Medical focuses on the research, development, production, and sales of high-end interventional medical devices [3] Group 3 - Jincheng Pharmaceutical's subsidiaries have been selected for the 11th batch of national drug centralized procurement [3] - Jincheng Pharmaceutical is engaged in the research, development, production, and sales of pharmaceutical intermediates and formulations [3] Group 4 - Zhongke Lanyun reported a 4.29% increase in revenue to 1.302 billion yuan and a 2.17% increase in net profit to 211 million yuan for the first three quarters [4] - The company specializes in wireless audio SoC chip research, design, and sales [5] Group 5 - Dabo Medical achieved a 22.69% increase in revenue to 1.876 billion yuan and a 77.03% increase in net profit to 425 million yuan for the first three quarters [6] - Dabo Medical focuses on the production, research, and sales of high-value medical consumables [7] Group 6 - Dayang Electric reported a 3.81% increase in revenue to 9.180 billion yuan and a 25.95% increase in net profit to 845 million yuan for the first three quarters [8][9] - The company operates in the electric motor sector, focusing on building and home appliance motors and automotive components [9] Group 7 - Fudan Microelectronics reported a 12.70% increase in revenue to 3.024 billion yuan but a 22.69% decrease in net profit to 330 million yuan for the first three quarters [10][11] - The company specializes in the design, development, and testing of large-scale integrated circuits [11] Group 8 - Shaanxi Energy reported a 2.83% decrease in revenue to 16.359 billion yuan and a 3.23% decrease in net profit to 2.417 billion yuan for the first three quarters [12][13] - The company is involved in thermal power generation and coal production and sales [13] Group 9 - Runhe Software reported a 12.86% increase in revenue to 2.719 billion yuan but a 29.01% decrease in net profit to 78.57 million yuan for the first three quarters [14][15] - The company focuses on financial technology, smart IoT, and smart energy [15] Group 10 - Shenzhen Gas reported an 8.63% increase in revenue to 22.528 billion yuan but a 13.08% decrease in net profit to 918 million yuan for the first three quarters [16][17] - The company specializes in urban gas supply and comprehensive energy services [17] Group 11 - Light Media reported a 150.81% increase in revenue to 3.616 billion yuan and a 406.78% increase in net profit to 2.336 billion yuan for the first three quarters [18][19] - The company is engaged in the investment, production, and distribution of film projects [19] Group 12 - Dazhong Mining's subsidiary obtained a mining license for the Hunan Jijiao Mountain lithium mine, with a resource amount of 490 million tons, equivalent to approximately 3.2443 million tons of lithium carbonate [19] - The company specializes in iron ore mining and production [19] Group 13 - Yirui Technology reported a 14.22% increase in revenue to 1.549 billion yuan and a 20.61% increase in net profit to 471 million yuan for the first three quarters [20] - The company focuses on the research, production, and sales of digital X-ray detectors and related solutions [20] Group 14 - TCL Zhonghuan reported a 4.48% decrease in revenue to 121.572 billion yuan and a net loss of 5.777 billion yuan for the first three quarters [21][22] - The company specializes in the research, production, and sales of photovoltaic silicon wafers, cells, and modules [22] Group 15 - Huangshan Tourism reported an 8.75% increase in revenue to 1.535 billion yuan but an 11.02% decrease in net profit to 253 million yuan for the first three quarters [23][24] - The company provides tourism and leisure services [24] Group 16 - Mountain Outside Mountain reported a 39.79% increase in revenue to 584 million yuan and a 68.68% increase in net profit to 105 million yuan for the first three quarters [25][26] - The company specializes in the research, production, and sales of blood purification equipment and services [26] Group 17 - Huajin Capital reported a 16.36% increase in revenue to 349 million yuan and a 185.62% increase in net profit to 104 million yuan for the first three quarters [27] - The company focuses on investment management and electronic device manufacturing [27] Group 18 - Datang Power reported a 1.82% decrease in revenue to 89.345 billion yuan but a 51.48% increase in net profit to 6.712 billion yuan for the first three quarters [28][29] - The company primarily engages in thermal power generation [29] Group 19 - Datang Power announced the acquisition of a 50% stake in Anhui Electric Power for 1 yuan, which will result in full ownership of Anhui Electric Power [30] - The company focuses on thermal power generation [30] Group 20 - Kairun Co. reported a 22.94% increase in revenue to 3.719 billion yuan but a 13.38% decrease in net profit to 278 million yuan for the first three quarters [31] - The company specializes in the research, design, production, and sales of leisure bags and related products [31] Group 21 - Dafu Technology reported a 1.95% increase in revenue to 1.764 billion yuan but a net loss of 170 million yuan for the first three quarters [32] - The company focuses on the research, production, and sales of RF products and automotive components [32] Group 22 - Dafu Technology plans to publicly transfer 49% of its stake in Dasheng Graphite [34] - The company specializes in the research, production, and sales of RF products and automotive components [34]

Core Viewpoint - Sino Medical (688108) experienced a significant decline in stock price, reaching a limit down of 20.01% to 20.15 CNY per share following the announcement of its product registration failure with the National Medical Products Administration (NMPA) [1] Group 1: Company Announcement - Sino Medical's subsidiary, Sino Shenchang Medical Technology Co., Ltd., received a notification from the NMPA on October 28 that its application for the COMETIU self-expanding intracranial drug-coated stent system was not approved for registration [1] - The company stated that the failure of the COMETIU stent's domestic registration will not have an immediate impact on its production and operations [1] - Sino Medical plans to continuously assess the long-term impact of the registration failure and will proceed with clinical, registration, and commercialization processes for the COMETIU stent in domestic, European, American, and global markets [1] Group 2: Future Plans - The company will make prudent operational arrangements based on objective conditions to ensure normal business operations and long-term sustainable development [1]

Core Viewpoint - Sino Medical (688108.SH) announced that its subsidiary, Sino Shenchang Medical Technology Co., Ltd., received a "medical device registration not approved" notice from the National Medical Products Administration (NMPA) for its COMETIU self-expanding intracranial drug-coated stent system [1] Group 1: Regulatory Approvals - The COMETIU stent's registration application was not approved by the NMPA, and the results have been publicly disclosed [1] - The company submitted an EU MDR certification application for the COMETIU stent to DEKRA Certification B.V. in October 2024, which has been accepted, and the product is currently in the final stage of technical review after passing the on-site quality system audit [1] Group 2: FDA Recognition - The COMETIU stent and COMEX balloon microcatheter received breakthrough medical device designation from the FDA in August 2025 [1] - This product is the first intracranial atherosclerotic stenosis treatment device to receive breakthrough designation in the history of the FDA's program and is also the first neuro-interventional device from China to achieve this recognition [1]

Major Events - *ST Zhengping's stock will be suspended for investigation starting October 29, 2025, due to a significant price increase of 152.42% from September 1 to October 28, 2025, with 21 days of trading halts and 5 instances of abnormal trading fluctuations [2] - Gongjin Co. announced that its major shareholder is planning a share transfer that may lead to a change in control, resulting in the stock being suspended from October 27, 2025, for up to 3 trading days [2] - Jiuquan Technology's wholly-owned subsidiary plans to invest 150 million yuan in establishing an industrial fund focused on chips and integrated circuits [2] Company Announcements - YN Holdings decided to terminate investment in 17 distributed photovoltaic projects originally planned for a total investment of 1.197 billion yuan due to changes in market conditions [3] - Awan New Materials announced a one-day stock suspension on October 29, 2025, due to a tender offer from Shanghai Zhiyuan Hengyue Technology Partnership, aiming to acquire 149,243,840 shares at 7.78 yuan per share [4] - Dahua Intelligent clarified that it currently has no business related to quantum technology despite market speculation [5] Financial Performance - Ganfeng Lithium reported a net profit of 557 million yuan for Q3 2025, a year-on-year increase of 364.02%, with revenues of 6.249 billion yuan, up 44.10% [6] - Light Media's net profit for Q3 2025 reached 1.06 billion yuan, a 993.71% increase, with revenues of 374 million yuan, up 247.54% [6] - Hainan Airport reported a net profit of 64.35 million yuan for the first three quarters of 2025, a decline of 69.77% [7] - Su Li Co. achieved a net profit of 59.42 million yuan in Q3 2025, a 2750% increase, with revenues of 762 million yuan, up 26% [7] - Yutong Bus reported a net profit of 1.357 billion yuan for Q3 2025, a 78.98% increase, with revenues of 10.237 billion yuan, up 32.27% [9] Share Buybacks - Haida Group plans to repurchase shares worth between 1 billion to 1.6 billion yuan for capital reduction and employee stock ownership plans, with a maximum price of 62 yuan per share [20] - Liyuan Information intends to repurchase shares totaling 20 million to 30 million yuan, with a maximum price of 15 yuan per share [21] Major Contracts - Baiao Intelligent won a project worth 97.22 million yuan from a large state-owned company [22] - Guangdong Construction signed a construction contract worth 1.924 billion yuan for a project in Guangzhou, which will enhance its business scale and profitability [22] - Guangqi Technology's subsidiary signed contracts for mass production of metamaterials worth a total of 215 million yuan [23]

Core Viewpoint - The domestic registration application for the self-expanding intracranial drug-coated stent system COMET I U by Sino Medical has not been approved by the National Medical Products Administration, but the global market approval process will continue [1] Group 1: Product Registration Status - Sino Medical's subsidiary, Sino Shenchang, did not receive approval for the domestic registration of the COMET I U product [1] - The product has passed the EU MDR on-site quality system audit and is in the final stage of technical review [1] - The product has also received breakthrough medical device designation from the US FDA [1] Group 2: Impact on Operations - The company will continue to advance the product's approval process in multiple countries and regions globally [1] - The lack of domestic registration approval is not expected to have a short-term impact on the company's production and operations [1]

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-049 赛诺医疗科学技术股份有限公司关于子公司 临床方案讨论会议。FDA 确认，基于本产品在中国境内开展的临床研究结果，COMETIU 支架 及 COMEX 球囊微导管将无需在美国开展针对产品的早期可行性临床研究（Early Feasibility Study），该产品可在美国直接开展关键确证性临床研究，以支持美国PMA（Pre-market Approval） 上市批准。 三、公司后续计划及安排 产品注册申请未获国家药监局批准 的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"） 控股子公司赛诺神畅 医疗科技有限公司（以下简称"赛诺神畅"或"子公司"）于 2025 年 10 月 28 日收到国家药监局 "医疗器械不予注册批件信息"，本公司 COMETIU 自膨式颅内药物涂层支架系统（以下简称 "COMETIU 支架"）的注册申请未获得国家药品监督管理局（以下简称"国家 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-050 赛诺医疗科学技术股份有限公司关于召开子公司 产品注册申请未获批准的投资者交流会通知公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、交流会类型 赛诺医疗科学技术股份股份有限公司（以下简称"赛诺医疗"或"公司"） 于 2025 年 10 月 30 日在上海证券交易所网站（http://www.sse.com.cn）上披露 了《赛诺医疗科学技术股份有限公司关于子公司产品注册申请未获国家药监局批 准的自愿性披露公告》。 为加强与投资者的深入交流，便于广大投资者更全面深入地了解本次子公司 产品注册申请未获国家药监局批准的情况以及公司后续经营发展情况，在上海证 券交易所的支持下，公司计划于 2025 年 10 月 30 日 15:30-17:00 在上证路演中 心（网址：https://roadshow.sseinfo.com/）以直播+网络互动的方式举行关于 子公司产品注册申请未获批准的投资者交流会，与广大投资者进行充分交流，解 答投 ...

Core Viewpoint - Sino Medical (688108) announced that its subsidiary, Sino Shenchang Medical Technology Co., Ltd., received a notification from the National Medical Products Administration (NMPA) stating that the registration application for its COMETIU self-expanding intracranial drug-coated stent system was not approved [1] Group 1 - The COMETIU stent's registration application was publicly disclosed as not approved by the NMPA on October 28 [1] - The company stated that the lack of domestic registration approval for the COMETIU stent will not have a short-term impact on its production and operations [1] - The company will continuously assess the long-term impact of the registration denial and will proceed with clinical, registration, and commercialization processes for the COMETIU stent in domestic, European, American, and global markets [1]

Core Viewpoint - Sino Medical announced that its subsidiary, Sino Shenchang, received a "medical device registration not approved" notice from the National Medical Products Administration for its COMETIU self-expanding intracranial drug-coated stent system, which was not approved for domestic registration. However, the product is making positive progress overseas, having passed the EU MDR on-site quality system audit and is in the final stage of technical review. It has also received breakthrough medical device designation from the FDA, allowing it to directly conduct pivotal confirmatory clinical studies. The company will advance its global commercialization, and the domestic registration denial will not have a short-term impact on production and operations [1]. Summary by Category Product Development - The COMETIU self-expanding intracranial drug-coated stent system did not receive domestic registration approval from the National Medical Products Administration [1] - The product has successfully passed the EU MDR on-site quality system audit and is in the final stage of technical review [1] - The product has received breakthrough medical device designation from the FDA, enabling the company to conduct pivotal confirmatory clinical studies directly [1] Business Impact - The company plans to push forward with global commercialization of the product [1] - The denial of domestic registration is not expected to impact production and operations in the short term [1]

Core Viewpoint - The company, Sainuo Medical, is currently in the registration process for its intracranial drug-eluting stent and has not yet received the review results from the regulatory agency [1] Group 1 - The company responded to investor inquiries on October 28 regarding the status of its intracranial drug-eluting stent [1] - The company will disclose the review results in accordance with legal regulations and requirements from regulatory agencies once they are received [1] - Investors are advised to pay attention to subsequent announcements on the Shanghai Stock Exchange website [1]